Compare ZVIA & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZVIA | HURA |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 123.0M |
| IPO Year | 2021 | 2010 |
| Metric | ZVIA | HURA |
|---|---|---|
| Price | $0.94 | $1.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $3.67 | ★ $8.04 |
| AVG Volume (30 Days) | 451.5K | ★ 547.2K |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.88 | 47.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $161,259,000.00 | N/A |
| Revenue This Year | $9.55 | N/A |
| Revenue Next Year | $6.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $0.96 | $0.41 |
| 52 Week High | $2.75 | $3.43 |
| Indicator | ZVIA | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 36.32 | 34.08 |
| Support Level | N/A | $1.27 |
| Resistance Level | $1.52 | $2.22 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 0.53 | 15.86 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.